Prima Mente
Prima Mente is a London-based AI biology company founded in 2022 that builds epigenetic and multi-omic foundation models (Pleiades, Parthenon, Prima Brain) to enable non-invasive blood-based early detection of Alzheimer's and Parkinson's disease, serving healthcare systems, academic researchers, and pharmaceutical partners.
- Company typePrivate
- Founded2022
- HeadquartersLondon, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingSoftware
What Prima Mente does
Prima Mente (legal entity: Prima Mente (CFDX Ltd), UK registration 14890974) is an AI biology company founded in 2022 and headquartered in London, with additional offices in San Francisco and the UAE. The company generates its own biological data, builds general-purpose biological foundation models, and translates those discoveries into research and clinical outcomes, with an initial focus on brain health and neurodegenerative disease. Its core product is Pleiades, a series of transformer-based whole-genome epigenetic foundation models (90M, 600M, and 7B parameters) trained on 1.9 trillion methylated and genomic tokens. Pleiades analyzes DNA methylation patterns in cell-free DNA from blood samples to enable non-invasive early detection of Alzheimer's and Parkinson's disease, with reported AuROC of 0.89 for combined Alzheimer's/Parkinson's detection, 0.97 for Alzheimer's when combined with the pTau-217 protein biomarker, and 0.84 for Parkinson's. The company is extending the platform with the Parthenon Series of multi-omic cellular models (launching early 2026, starting with microglia) and the Prima Brain Foundation Model for novel therapeutic target discovery, and conducts mechanistic interpretability research with Goodfire AI to identify novel biomarkers from model internals.
Prima Mente runs two clinical research programs to validate its technology in real-world settings. The SANDBOX study is a landmark initiative across 15 NHS Memory Clinics in the UK aiming to recruit over 1,000 patients, combining blood biomarkers and genotyping with remote cognitive testing for earlier detection of cognitive decline. The READOUT study is the UK's leading dementia diagnostics effort, led by the University of Oxford with NIHR support, in which Prima Mente generates longitudinal clinical and multi-omic data for disease risk modeling. The company is also a participant in the Longitude Prize on ALS, extending its foundation model platform into amyotrophic lateral sclerosis drug discovery.
The company's revenue model is built around B2B research partnerships with healthcare systems, academic institutions, and pharmaceutical companies, with grant and prize funding (e.g., the $1M Alzheimer's Insights AI Prize from the Alzheimer's Disease Data Initiative, a £100,000 Longitude Prize Discovery Award) supplementing current inflows. Future revenue is expected from licensing the Pleiades, Parthenon, and Prima Brain foundation models to pharmaceutical partners for drug discovery and patient stratification, and potentially from in-house therapeutic development. Go-to-market is sales-led and relationship-driven, anchored in NHS, UK university, and global academic partners (Oxford, Edinburgh, Stanford, Salk, Dementia Platform UK, Davos Alzheimer's Collaborative), with compute infrastructure provided by NVIDIA Inception, Nebius AI Cloud, and the UK Government's £500M Sovereign AI initiative (up to 1M GPU hours). The company is UK GDPR compliant (ICO registration ZC112984) and operates clinical research under GCP (ICH E6) standards via the Health Research Authority and MHRA frameworks.
Prima Mente firmographics
Firmographics- Name
- Prima Mente
- Legal name
- Prima Mente (CFDX Ltd)
- Website
- https://primamente.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Short description
- Prima Mente is a London-based AI biology company founded in 2022 that builds epigenetic and multi-omic foundation models (Pleiades, Parthenon, Prima Brain) to enable non-invasive blood-based early detection of Alzheimer's and Parkinson's disease, serving healthcare systems, academic researchers, and pharmaceutical partners.
- Ownership category
- akta.pro rank
Prima Mente industry classification
Industry- Product category
- AI Foundation Models for Neurodegenerative Disease Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Proteomics & Mass Spectrometry Services (HLAGANAB), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Prima Mente is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Prima Mente business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Research Partnerships & Collaborations: Revenue generated through research partnerships with academic institutions, healthcare systems, and pharmaceutical companies. Includes clinical study collaborations and data sharing agreements.
- Foundation Model Licensing: Potential licensing of biological foundation models (Pleiades, Parthenon) to pharmaceutical companies for drug discovery and target identification applications.
- Therapeutic Development: Company is exploring in-house therapeutic development based on biological insights from foundation models, representing potential future revenue stream.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Prima Mente product offering
Product offeringCore offering
Prima Mente develops biological foundation models, including the Pleiades series, trained on 1.9 trillion methylated and genomic tokens from the human epigenome. The company analyzes DNA methylation patterns in blood-derived cell-free DNA to enable non-invasive early detection of Alzheimer's and Parkinson's disease, achieving 89% accuracy (97% combined with protein biomarkers). The company also runs large-scale clinical research studies (SANDBOX, READOUT) and generates proprietary biological data to train and validate its foundation models for research and clinical applications.
Product overview
Prima Mente is an AI biology company that develops biological foundation models for understanding and treating neurological disease. The core product is Pleiades, a whole-genome epigenetic foundation model that analyzes DNA methylation from blood samples for early detection of Alzheimer's and Parkinson's disease. Building on Pleiades, the Parthenon Series will extend into multi-omic biological models for brain cell types, while the Prima Brain Foundation Model (in development) aims at novel target discovery for drug development. The company operates two clinical validation studies: SANDBOX across 15 NHS sites validating Pleiades in real-world settings, and READOUT (led by Oxford University) generating longitudinal -omics data for dementia research. The company generates its own biological data, builds foundation models, and translates discoveries into clinical outcomes.
Differentiator
Problem solved
Functional benefit
Products and services
- Pleiades Foundation Model Series A series of transformer-based whole-genome epigenetic foundation models (90M, 600M, and 7B parameters) trained on 1.9 trillion methylated and genomic tokens. It analyzes DNA methylation changes in blood-derived cell-free DNA to enable early detection of Alzheimer's and Parkinson's disease. It is sold/licensed to research institutions, healthcare systems, and pharmaceutical companies for diagnostic, biomarker discovery, and drug discovery applications.
Quantifiable outcome
- 89% accuracy for early-stage Alzheimer's and Parkinson's detection from blood samples
- +4 more outcomes
Companies that use Prima Mente
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Prima Mente technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Prima Mente partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- NVIDIAcoreNVIDIA Inception member with joint case study publication. Prima Mente uses NVIDIA infrastructure and GPU technology for training biological foundation models. The partnership enables large-scale AI model training on Nebius AI Cloud powered by NVIDIA hardware.
- NebiuscoreNebius AI Cloud provides GPU infrastructure for Prima Mente's biological foundation model training. Prima Mente runs biological foundation model training on Nebius for Alzheimer's and Parkinson's research. Nebius has invested approximately £1.7 billion in UK AI infrastructure expansion.
- Goodfire AIcoreJoint research on mechanistic interpretability to identify novel Alzheimer's biomarkers. Goodfire and Prima Mente published research blog on using interpretability methods to interrogate Pleiades model and discover DNA fragment length patterns as biomarkers.
- University of OxfordcoreIndustry partner in READOUT dementia diagnostics study led by University of Oxford and supported by NIHR. Prima Mente generates rich longitudinal clinical and omics data for disease risk modeling.
- University of EdinburghmajorAcademic collaborator providing research capabilities and access to UK AI infrastructure. Partnership contributes to UK Sovereign AI ecosystem development.
- Salk Institute for Biological StudiesmajorAcademic research collaborator with access to leading biological research capabilities and expertise in neuroscience.
- Dementia Platform UKmajorResearch partner providing access to dementia research infrastructure and patient cohort data for validation studies.
- Davos Alzheimer's CollaborativemajorGlobal partnership focused on accelerating Alzheimer's research and treatment development through coordinated international efforts.
- Stanford UniversitymajorAcademic collaborator providing access to leading research capabilities and expertise in Alzheimer's and neuroscience research.
- University of JerusalemminorAcademic research collaborator contributing to international research network capabilities.
- University of GothenburgminorAcademic research collaborator contributing to international research network capabilities.
- Office for Life SciencesmajorUK government partner providing access to life sciences research support and policy frameworks for healthcare innovation.
Scale indicators5 records
Recent moves6 records
Expansion highlights7 records
Prima Mente competitors and assessment
Company assessmentDirect peers
- Owkin: AI-for-healthcare platform building foundation models and federated-learning tools on multimodal patient data for biopharma R&D and diagnostics. Closest peer in business model: B2B partnerships with hospitals and pharma, foundation-model-plus-clinical-evidence go-to-market.
- Insitro: AI biology company combining proprietary data generation with machine learning models for drug discovery and target identification. Comparable because of its data-to-model-to-therapeutics pipeline and B2B pharma orientation.
- Recursion Pharmaceuticals: AI-driven drug discovery company generating proprietary biological data and training foundation models to accelerate therapeutic programs. Overlaps with Prima Mente on the data-generation-plus-foundation-model thesis in life sciences.
- C2N Diagnostics: Commercial blood-based Alzheimer's diagnostics company (PrecivityAD) measuring pTau-217 and other plasma biomarkers. Most direct diagnostic competitor to Pleiades and an existing Prima Mente collaborator for plasma biomarker analysis.
- SOPHiA Genetics: AI-driven genomics platform that ingests next-generation sequencing data and produces clinical insights for hospitals and labs. Comparable on AI-over-omics, hospital-system B2B channel, and recurring software economics.
- Tempus AI: AI precision-medicine company combining multi-omic data, clinical records, and AI models to support diagnostics and biopharma R&D. Comparable for multi-omic foundation-model approach and pharma/hospital customer base.
- Isomorphic Labs: Alphabet-founded AI drug discovery company building biological foundation models to accelerate therapeutic discovery. Direct analogue as a foundation-models-for-biology company with pharma partnerships at the core of its GTM.
Broad incumbents
- Foundation Medicine (Roche): Large established genomic-profiling and companion-diagnostics business within Roche, serving oncologists and biopharma. Comparable as a genomics-driven diagnostics player but broader and better capitalized, and focused on oncology rather than neuro.
Emerging players
- BenevolentAI: UK-based AI drug discovery company using knowledge graphs and machine learning to identify novel targets, with a pipeline skewed toward neurodegenerative and inflammatory disease. Comparable target-discovery angle and UK footprint.
- Quanterix: Ultra-sensitive biomarker measurement platform (Simoa) widely used in neurodegenerative disease research and increasingly in plasma-based Alzheimer's diagnostics. Comparable on blood-based biomarker infrastructure that could compete with or complement Pleiades.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Prima Mente social profiles
Digital presencePrima Mente compliance and trust
Trust signalCompliance3 records
Prima Mente financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prima Mente leadership team
Management profileNumber of profiles
Profiles4 records
Prima Mente funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prima Mente M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prima Mente
What does Prima Mente do?
Prima Mente develops biological foundation models, including the Pleiades series, trained on 1.9 trillion methylated and genomic tokens from the human epigenome. The company analyzes DNA methylation patterns in blood-derived cell-free DNA to enable non-invasive early detection of Alzheimer's and Parkinson's disease, achieving 89% accuracy (97% combined with protein biomarkers). The company also runs large-scale clinical research studies (SANDBOX, READOUT) and generates proprietary biological data to train and validate its foundation models for research and clinical applications.
Is Prima Mente a public or private company?
Prima Mente is a private company. It is classified as unknown and is currently operating.
When was Prima Mente founded?
Prima Mente was founded in 2022.
Where is Prima Mente based?
Prima Mente is headquartered in London, United Kingdom, in the Europe region.
How does Prima Mente make money?
Three revenue lines are on record. Research Partnerships & Collaborations are the primary driver. The others are foundation Model Licensing and therapeutic Development.
Who are Prima Mente's main competitors?
Direct peers on record are Owkin, Insitro, Recursion Pharmaceuticals, C2N Diagnostics, SOPHiA Genetics, Tempus AI and Isomorphic Labs. Foundation Medicine (Roche) is listed as a broad incumbent. Emerging players are BenevolentAI and Quanterix.
Does Prima Mente have an API?
No public API is recorded for Prima Mente.
What industry is Prima Mente in?
Prima Mente's product category is AI Foundation Models for Neurodegenerative Disease Diagnostics. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2835.